ROCHE REMAINS A BELLWETHER, DESPITE RECENT (R&D) JITTERS (ADD; 14% UPSIDE)
19/09/22 -" Since early 2022, an already fragile global economy (surfing on monetary excesses) has faced several challenges – spiralling inflation and supply-chain disruptions – due to the war in Europe, ..."
Pages
68
Language
English
Published on
19/09/22
You may also be interested by these reports :
21/09/26
Novo’s CMD announcements, including the diversification plan and a vague mid-term sales target, disappointed investors. Against the backdrop of ...
21/09/26
Siegfried’s (Buy, Switzerland) post-Covid success story has been nipped in the bud by three years of low-single-digit (LSD) growth (in CHF). ...
17/09/26
Although our estimates have increased by double digits, the target price has been raised at a lower rate due to Ipsen’s near- and mid-term risks. ...
15/09/26
At a time when Novartis and AstraZeneca nurse a run of late-stage R&D setbacks, GSK’s recent clinical trial successes for oncology candidates, ...